Crovalimab (Roche/Genentech, South San Francisco, CA, USA), another mAb that targets an epitope on the C5 β chain (whereas Eculizumab and Ravulizumab bind to the C5 α chain [90]), is currently under investigation in a randomized phase Ib study for the management of acute uncomplicated vaso-occlusive episodes in sickle cell disease, a condition characterized by microvascular dysfunction associated with IRI [91]. Here, C5 is linked to sickle cell disease.